Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

Published:2018-06-05 Issue:4 Volume:182 Page:504-512
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Jones Jeffrey¹^ORCID,Mato Anthony²³^ORCID,Coutre Steven⁴,Byrd John C.¹,Furman Richard R.⁵,Hillmen Peter⁶,Osterborg Anders⁷,Tam Constantine⁸,Stilgenbauer Stephan⁹,Wierda William G.¹⁰^ORCID,Heerema Nyla A.¹,Eckert Karl¹¹,Clow Fong¹¹,Zhou Cathy¹¹,Chu Alvina D.¹¹,James Danelle F.¹¹,O'Brien Susan M.¹²

Affiliation:

1. Ohio State University Comprehensive Cancer Center; Columbus OH USA

2. University of Pennsylvania; Philadelphia PA USA

3. Hackensack University Medical Center; Hackensack NJ USA

4. Stanford University School of Medicine; Stanford CA USA

5. Weill Cornell Medical College; New York NY USA

6. Leeds Teaching Hospitals NHS Trust; St. James Institute of Oncology; Leeds UK

7. Karolinska University Hospital Solna; Stockholm Sweden

8. Peter MacCallum Cancer Centre and St. Vincent's Hospital; Melbourne Australia

9. University of Ulm; Ulm Germany

10. The University of Texas MD Anderson Cancer Center; Houston TX USA

11. Pharmacyclics LLC, an AbbVie Company; Sunnyvale CA USA

12. Chao Family Comprehensive Cancer Center; University of California; Irvine CA USA

Funder

AbbVie

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15421/fullpdf

Reference34 articles.

1. Cell-intrinsic determinants of ibrutinib-induced apoptosis in chronic lymphocytic leukemia;Amin;Clinical Cancer Research,2016

2. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia;Badoux;Blood,2011

3. Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis;Brejcha;Leukemia Research,2014

4. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study;Burger;The Lancet Oncology,2014

5. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;New England Journal of Medicine,2013

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia;Clinical and Experimental Medicine;2023-10-13

2. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study;Medicina;2023-02-09

3. Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment;Computational and Mathematical Methods in Medicine;2022-10-03

4. ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review;OncoTargets and Therapy;2022-10

5. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies;Journal of Hematology & Oncology;2022-10-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3